Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 2/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2972658 | 0.89 | CYP1A2 (0.35) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2975608 | 0.77 | MEN1 (0.36) | MEN1KMT2ALMNACYP1A2CYP2C9 | |
| SCHEMBL2963911 | 0.72 | GID4 (0.33) | CACNA1D | |
| SCHEMBL2962283 | 0.68 | MAPK1 (0.39) | MEN1KMT2ACYP1A2PGRCACNA1D | |
| SCHEMBL28110274 | 0.66 | GSK3A (0.34) | MEN1KMT2ALMNANPY1RALDH1A1 | |
| SCHEMBL2970691 | 0.66 | MEN1 (0.33) | MEN1KMT2ALMNACYP1A2CYP2C9 | |
| SCHEMBL14701534 | 0.66 | MEN1 (0.42) | MEN1KMT2ALMNACYP1A2GAA | |
| SCHEMBL2962539 | 0.65 | TP53 (0.35) | LMNAGAAPGR | |
| SCHEMBL2963093 | 0.65 | ALDH1A1 (0.39) | MEN1KMT2APGRCACNA1DALDH1A1 | |
| SCHEMBL6517710 | 0.64 | PTGDR2 (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763562-B2 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | AP2M1, AP1M1, PYM1 | MEN1 750/4885KMT2A 1517/4885LMNA 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.